Isaac Barchas Sells 83,094 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 83,094 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $24.11, for a total value of $2,003,396.34. Following the sale, the director directly owned 125,410 shares in the company, valued at $3,023,635.10. This trade represents a 39.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total value of $409,125.20.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Price Performance

IMNM stock traded up $0.49 during midday trading on Tuesday, hitting $24.39. 1,561,508 shares of the stock traded hands, compared to its average volume of 1,722,826. The firm has a market cap of $2.76 billion, a P/E ratio of -10.25 and a beta of 2.07. The stock’s fifty day simple moving average is $20.99 and its 200-day simple moving average is $21.83. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, research analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. lifted its stake in Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA boosted its holdings in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares in the last quarter. State Street Corp increased its position in Immunome by 37.9% during the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after buying an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Wedbush reissued an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research note on Friday, June 12th. Leerink Partners decreased their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Barclays started coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and an average price target of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.